Related Experiment Videos
Therapeutic approaches for ophthalmic problems in juvenile rheumatoid arthritis
1Harvard Medical School, Boston, Massachusetts.
Insights
Juvenile rheumatoid arthritis (JRA) is a chronic childhood disease causing pain and disability. Effective management requires balancing treatment benefits against risks, especially for eye complications, to prevent permanent vision loss.
Area of Science:
- Pediatric Rheumatology
- Ophthalmology
Background:
- Juvenile rheumatoid arthritis (JRA) is a chronic, painful childhood disease.
- JRA can lead to permanent disability, blindness, and treatment-related complications.
- Managing JRA involves balancing therapeutic efficacy with treatment morbidity, particularly for ocular manifestations.
Purpose of the Study:
- To highlight the challenges in managing JRA, focusing on ocular disease.
- To emphasize the importance of parent-child discussions in therapeutic decision-making.
- To outline strategies for preventing and managing visual compromise in JRA patients.
Main Methods:
- Careful classification of JRA patients to identify those at high risk for ocular disease.
- Frequent ophthalmologic screening examinations for at-risk children.
- Close monitoring for ocular side effects of systemic JRA therapies.
Main Results:
- Early intervention and aggressive management of intraocular inflammation are crucial.
- Minimizing intraocular inflammation reduces morbidity and permanent visual compromise.
- Surgical interventions for JRA-related ocular conditions require careful consideration of perioperative inflammation risks.
Conclusions:
- Aggressive medical management and regular screening can prevent vision loss in JRA.
- Ophthalmologic monitoring is essential to detect and manage ocular side effects of JRA treatment.
- Surgical considerations in JRA patients must account for increased perioperative inflammation and complications.
Abstract:
Juvenile rheumatoid arthritis is a disease of children which is chronic and painful, with the potential to produce permanent disability and blindness in a significant portion of cases. The treatment we provide these children may also disable them. Managing this disease process and caring for these patients is a challenging task in which therapeutic efficacy must be continually balanced against treatment morbidity. With respect to ocular disease, we must particularly recognize the difficulties parents have in treating a characteristically asymptomatic process with interventions that can produce unpleasant symptomatology. The importance of discussion of therapeutic decisions with parent and child cannot be overemphasized. Children with JRA should be carefully classified and those at greatest risk for development of ocular disease should receive frequent ophthalmologic screening exams. Early intervention and aggressive medical management of intraocular inflammation will minimize morbidity and permanent visual compromise. Patients should also be closely monitored for ocular side effects of therapies directed against articular disease. Procedures employed for treatment of cataract, glaucoma, corneal, and vitreal opacities must take into account the risk and complications of surgical intervention in the JRA patient prone to perioperative inflammation.